FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts

Revolution Medicines shares fall on new FDA review documents for Rasonque

Revolution Medicines' stock dropped after FDA review documents suggested Rasonque might not be as broadly effective as previously thought, raising concerns about the drug's approval prospects.